MolPharm Over 1500 Individual Drug Articles!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on June 7, 2006; DOI: 10.1124/mol.106.025346


0026-895X/06/7003-838-850$20.00
Mol Pharmacol 70:838-850, 2006

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.025346v1
70/3/838    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zeitoun, O.
Right arrow Articles by Bahouth, S. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zeitoun, O.
Right arrow Articles by Bahouth, S. W.

Mutagenesis within Helix 6 of the Human beta1-Adrenergic Receptor Identifies Lysine324 as a Residue Involved in Imparting the High-Affinity Binding State of Agonists

Omeima Zeitoun, Noel M. Delos Santos, Lidia A. Gardner, Stephen W. White, and Suleiman W. Bahouth

Department of Pharmacology, the University of Tennessee Health Sciences Center, Memphis, Tennessee (O.Z., N.M.D., L.A.G., S.W.B.); and Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, Tennessee (S.W.W.)

Received April 4, 2006; accepted June 5, 2006


    Abstract
 Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 
Competition binding isotherms for agonists to G protein-coupled receptors (GPCR) display high and low binding affinities. Mutagenesis of lysine at position 324 in helix 6 of the wild-type (WT) human beta1-adrenergic receptor (beta1-AR) generated mutant receptors that had GTP-insensitive single low-affinity binding sites for agonists and reduced potencies of full or partial agonists in stimulating adenylyl cyclase. Unlike the WT beta1-AR, intrinsic activities of full and partial agonists in activating the Lys324-> Ala beta1-AR (K324A) mutant were correlated with their binding affinities to the K324A mutant. In assays, such as agonist-mediated phosphorylation and recycling, the K324A mutant and the WT beta1-AR behaved similarly. However, in fluorescence resonance energy transfer assays that determined the proximity between the WT beta1-AR or the K324A mutant to Gs{alpha}, there were significant differences. The conceptual framework of the ternary complex model could not adequately account for the behavior of the K324A mutant except under assumptions of low receptor-G protein binding affinities. The single low-affinity binding site of the K324A mutant to isoproterenol was converted by the C-terminal 11-amino-acid peptide of Gs{alpha}, which acts a GDP-bound Gs{alpha} mimic, to high- and low-affinity sites. Based upon the three-dimensional architecture of the human beta1-AR, the distance between Lys324 and the Asp/Glu-Arg-Tyr motif in helix 3 was the shortest among the various amino acids in helix 6. These findings indicate that Lys324 lies in a groove between helices 3 and 6, and its mutagenesis generates a mutant receptor with very low binding affinity for the GDP-bound isoform of Gs.


GPCRs are key bridging molecules between extracellular stimuli such as hormones and neurotransmitters and intracellular signaling cascades. Receptors are multidomain molecules with separate entities for ligand binding, G protein activation, desensitization, and sequestration (Gether et al., 2002Go). Ligand-activated receptors activate their respective G proteins by promoting the exchange of GTP for GPD bound to the {alpha} subunit of the heterotrimer (Gether and Kobilka, 1998Go). GTP for GPD exchange causes the liberation and dissociation of {alpha}-GTP from beta{gamma} complexes that in turn activate the effector enzyme (Bourne, 1997Go).

The observation that agonists, but not antagonists, stabilize an active conformation of the receptor is based on classic theories of receptor activation. This active receptor conformation consists of the agonist, the receptor, and the G protein in a ternary complex that promotes the biological response (De Lean et al., 1980Go). The proportion of receptors with this active conformation is determined by means of competition radioligand binding assays in which a constant concentration of a radiolabeled antagonist competes with increasing concentrations of the full agonist. These two-site binding isotherms are then analyzed by nonlinear regression to estimate the population of receptors that display high affinity for the agonist versus those with low affinity. The percentage of receptors that display high-affinity equates the active form of the receptor with a ternary complex involving the agonist, the receptor, and the G protein (Stiles et al., 1984Go). The percentage of receptors with low-affinity equates those receptors that are uncoupled from the G protein and consequently unable to promote the biological response.

The role of helix 6 has gained prominence as a pivotal helix in transducing agonist binding to the GPCR into activation of the receptor associated G protein heterotrimer (Farrens et al., 1996Go). This mechanism proposes that agonist-mediated activation of GPCR leads to breaking and establishing of interactions between the Asp/Glu-Arg-Tyr [i.e., (D/E)RY motif] in helix 3 and helix 6 that applies to rhodopsin, the beta2-AR, and other GPCRs (Farrens et al., 1996Go; Gether et al., 1997Go; Ballestero et al., 2001Go). By means of histidine substitutions in helices 3 and 6 of the human beta2-AR and the parathyroid receptor, Sheikh et al. (1999Go) determined the residues in helix 6 that were capable of forming zinc(II) bridges as those involved in agonist-mediated activation of Gs. However, the zinc(II) bridging method failed to identify residues in helix 6 that were involved in regulating the agonist binding affinity to the beta2-AR. After the publication of this article, the crystal structure of dark-adapted rhodopsin revealed that helices 3 and 6 were extended {alpha}-helices that project as an {alpha}-helix beyond the sequence that is buried in the lipid core of the membrane (Palczewski et al., 2000Go). The three-dimensional structure of the human beta1-AR was modeled based upon the crystal structure of rhodopsin to estimate the distances between the various amino acids in helix 6 relative to the (D/E)RY region in helix 3. Based upon these measurements and additional site-directed mutagenesis in helix 6, we identified a residue in helix 6 that is involved in imparting the high-affinity binding characteristics of the human beta1-AR to agonists.


    Materials and Methods
 Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 
Site-Directed Mutagenesis. The Flag-tagged human beta1-AR flanked with HindIII (5') and EcoRI (3') sites was cloned into the multiple cloning site in the pUC18 plasmid (Delos Santos et al., 2006Go). Point mutations in helix 6 were generated by site-directed mutagenesis, using the Transformer system (BD Biosciences, San Jose, CA). The sequences of mutated receptors were verified by dideoxy sequencing, followed by cloning of each mutated full-length beta1-AR cDNA into the mammalian expression vector pCDNA-3.1 (Invitrogen, Carlsbad CA).

Cell Culture and Transient Transfections. HEK-293 cells were cultured in DMEM supplemented with 10% fetal bovine serum until they were ~90% confluent. The WT beta1-AR or its point-mutants in pCDNA 3.1 were transiently transfected into HEK-293 cells using the Cytofectene reagent (Bio-Rad Laboratories, Hercules, CA) as follows. Plasmid DNA (5 µg) was diluted into 200 µl of DMEM and then mixed with an equal volume of DMEM containing 12 µl of Cytofectene at room temperature for 30 min. Then 4 ml of DMEM was added, and the DNA-lipid complex was layered over the cells for 5 h at 37°C. Then, an equal volume of DMEM + 10% FBS was added to each culture dish, and the cells were cultured for an additional 36 h.

Membrane Preparation. Transiently transfected cells on 10-cm culture plates were washed twice with 10 ml of ice-cold PBS, then scraped from the plates and pelleted by centrifugation at 2000g for 10 min. The cell pellets were suspended in 10 ml of hypotonic buffer composed of 20 mM HEPES, pH 7.4, 2 mM MgCl2, 1 mM EDTA, and 1 mM 2-mercaptoethanol supplemented with 10 µg/ml leupeptin and 10 µg/ml aprotinin with or without 1 mM phenylmethylsulfonyl fluoride for 10 min on ice. The cells were transferred into a glassglass homogenizer and lysed by 30 up-and-down strokes. Cell lysates were centrifuged at 2500g for 5 min to pellet the nuclei, and the supernatant was centrifuged at 15,000g for 20 min to pellet the membranes. Membrane proteins were resuspended into 50 mM Tris-HCl, pH 7.5, and 10 mM MgCl2 with protease inhibitors.

Radioligand Binding Assays for beta1-AR. Binding of [125I]iodocyanopindolol (ICYP) to 0.5 µg of membranes was measured in 50 mM Tris-HCl, pH 7.4, plus 10 mM MgCl2 binding buffer containing 0.1 mM ascorbic acid for 2 h at 25°C. For saturation binding experiments, ICYP concentrations ranging from 5 to 300 pM were used. From these experiments, the affinity (KD) and the maximal density of receptors (Bmax) for ICYP binding to each beta1-AR subtype were generated by parametric fitting of the data using the Prism 4 software (GraphPad, San Diego, CA). For competition binding experiments, 70 pM ICYP was competed with 24 increasing concentrations of unlabeled competitor ranging from 0.1 nM to 10 µM. The IC50 (high) and IC50 (low) values for isoproterenol were derived from two-compartment competition to the -GTP data. The IC50 values were converted to the corresponding KIH (high) and KIL (low) values using the equation

Formula(1)

Each saturation and competition experiment was performed in triplicate and replicated between three and five times to determine the mean ± S.E. The log-affinity-shift for each beta-agonist toward the WT beta1-AR or the K324A mutant construct was calculated as the log of the ratio of KL/KH that was derived from four independent determinations.

Cyclic AMP Accumulation and Adenylyl Cyclase Assays. Transiently transfected cells in six-well plates were switched to DMEM + 25 mM HEPES for 2 h. Appropriate concentrations of isoproterenol in DMEM/HEPES, supplemented with a 300 µM concentration of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX) were added to the cells for 10 min at 37°C. The reaction was stopped by rapid aspiration of the culture medium and addition of 1 ml of 0.1 N concentrations of isoproterenol HCl followed by freezing of the entire plate in liquid nitrogen. Frozen plates were quickly thawed at 65°C to break the cells, and the cell extract was lyophilized. The dry pellet was resuspended in assay buffer, and cyclic AMP was quantified by radioimmunoassay (RIANEN Assay System; PerkinElmer Life and Analytical Sciences, Boston, MA) and expressed as picomoles of cyclic AMP accumulated per minute per milligram of cell protein using a standard curve that was run in parallel.

For the determination of adenylyl cyclase activity, membranes were prepared from transiently transfected cells without phenylmethylsulfonyl fluoride. Fifty micrograms of membrane proteins were incubated in a final volume of 0.1 ml in buffer containing 50 mM Tris-HCl, pH 7.4, 1 mM MgCl2, 10 mM phosphocreatine, 1 mM cyclic AMP, 2 mM mercaptoethanol, 1 mg/ml bovine serum albumin, 0.4 mM EGTA, 2 mg/ml creatine kinase, and 0.2 mM ATP containing 2 µCi of [{alpha}-32P]ATP, 1 mM GTP, and increasing concentration of isoproterenol from 0.1 nM to 0.1 mM. The assay was initiated by the addition of membranes and terminated after 10 min. Cyclic AMP that was formed was separated from ATP by column chromatography, and its specific activity was determined as cyclic AMP formed in picomoles per minute per milligram of protein. The amounts of cyclic AMP formed for each condition were divided by the amounts of cyclic AMP generated by 0.1 mM isoproterenol to estimate the percentage ± S.E. of maximal cyclic AMP generated from each beta1-AR construct. The intrinsic activities on WT beta1-AR or the K324A mutant were defined as the ratios for the maximal activation of adenylyl cyclase by a given beta-agonist divided by the activation achieved by 0.1 mM isoproterenol. The data are presented as the mean ± S.E. of the intrinsic activity based upon four determinations for each beta-agonist toward the WT or mutant beta1-AR.

Intact Cell Phosphorylation and beta1-AR Immunoprecipitation. Cell cultures were switched to phosphate-free DMEM supplemented with 12.5 mM HEPES for 60 min. Then they were incubated with 100 µCi of 32Pi/ml for 2 h at 37°C to equilibrate the [32P]ATP pools. The cells were exposed to 1 mM ascorbic acid (control) or 10 µM isoproterenol for 10 min at 37°C, followed by rapid aspiration of this medium. The cells were lysed with 1 ml/plate of ice-cold radioimmunoprecipitation assay + SDS buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, and 0.2% SDS supplemented with protease and phosphatase inhibitors) was added. After scrapping, the lysates were sonicated briefly then centrifuged at 14,000g for 5 min at 4°C. From the supernatant, two 5-µl aliquots were removed for protein assay. The remaining volume was processed for immunoprecipitation; each step thereafter was conducted at 0-4°C. Equal amounts of cell lysates were incubated with 40 µl of anti-Flag M2 IgG-agarose beads (Sigma, St. Louis, MO) and incubated at 4°C overnight on a rotating platform. The resin was washed five times with 1 ml of ice-cold radioimmunoprecipitation assay buffer, then 100 µl of Laemmli sample buffer containing 20 mM dithiothreitol was added, and the slurry was incubated at 37°C for 40 min to release the IgG-beta1-AR complex from the resin. The proteins were separated by electrophoresis in 10% acrylamide gels containing 0.1% SDS, dried, and exposed to autoradiography. The relative amounts of 32P-incorporated into the beta1-AR band were determined by electronic counting of the gel by the InstantImager (PerkinElmer Life and Analytical Sciences).

Acid Strip Confocal Recycling Microscopy Protocol. HEK-293 cells expressing the FLAG-tagged WT beta1-AR or FLAG-tagged K324A mutant were grown on poly-L-lysine-coated glass coverslips and serum-starved at 37°C for 1 h in DMEM supplemented with 25 mM HEPES, pH 7.4. The receptors were labeled with 5 µg/ml of FITC-conjugated anti-Flag M2 IgG (Sigma) for 1 h at 37°C. Cells were treated with 10 µM isoproterenol for 30 min at 37°C to promote agonist-mediated receptor internalization. The cells were then chilled in 4°C Tris-buffered saline to stop endocytosis and exposed to 0.5 M NaCl and 0.2 M acetic acid, pH 3.5, for 4 min on ice to remove antibody bound to the beta1-AR (Snyder et al., 2001Go; Gardner et al., 2004Go; Delos Santos et al., 2006Go). Cultures were quickly rinsed in warm DMEM supplemented with HEPES, then incubated with a 100 µM concentration of the beta-antagonist alprenolol at 37°C for 10, 20, 30, or 45 min. After each time period, the cover slips were rinsed and fixed in 4% paraformaldehyde in 4% sucrose in phosphate-buffered saline, pH 7.4, for 10 min at room temperature.

Analysis of Immunocytochemical Data. All analyses were performed blind to the stimulation history of the culture. Microscope fields had one to three cells displaying generally healthy morphology. Six to ten cells were imaged per culture, and 10 cultures were processed per condition. Confocal fluorescence microscopy was performed on all the slides using Zeiss Axiovert LSM 510 (100 x 1.4 differential interference contrast oil immersion objective). FITC was excited with the argon laser at 488 nm and imaged through the long-pass emission filter at 520 nm. Thresholds were set by visual inspection and kept constant for each condition. Z-stacks of images were exported as TIFF files, and individual sections were analyzed with Zeiss LSM 510 and NIH Image 1.6 software (http://rsb.info.nih.gov/nih-image/) as described in Delos Santos et al. (2006Go). In confocal recycling assays, the time constants (t) for beta1-AR recycling were determined by fitting the data to a single exponential decay function of the from of

Formula(2)

In eq. 2, yo and A are constants. The data represent the mean of the recycling time ± S.E. from five slides, each involving between 6 and 10 cells.

Data Analysis. Quantitative data were summarized and presented as means and S.E. from at least four determinations, each from triplicate experiments. Least-squares linear regression and nonlinear curves were calculated by the Prism 4.05 program (Graph-Pad) to estimate the Kact of each beta1-AR in stimulating the activity of adenylyl cyclase. Statistical comparisons between samples were analyzed by analysis of variance with Duncan's post hoc test using Prism 4.05 software.

Fluorescence Resonance Energy Transfer Microscopy. These experiments were performed on fixed cells using the sensitized emission method (Kenworthy, 2001Go). The coding sequences of the Flag-tagged WT beta1-AR or the K324A mutant were amplified by polymerase chain reaction using synthetic oligonucleotides to introduce a 5' HindIII site followed by the coding sequence and then by a 3' BamHI site. The amplification primers for the beta1-AR were: forward, 5'-AAGCTTATGGACTACAAGGACGACGATGACAAGGGCGCGGGGGTGCTCGTCCTGGGCG; reverse, TGGATCCACCTTGGATTCCGAGGCGAAGCC. The resulting 1.5-kilobase HindIIIBamHI cDNA was fused in-frame 5' to the yellow fluorescent protein (YFP) coding sequence in the pECYFP-N1 vectors (BD Biosciences, San Jose, CA) to generate N-terminal fusions of each beta1-AR to YFP. The Gs{alpha}-cyan fluorescent protein (CFP) vector (Hynes et al., 2004Go) was provided by C. Berlot (Weis Center for Research, Geisinger Clinic, Danville, PA).

HEK-293 cells were transfected with the desired plasmids using the Lipofectamine reagent (Invitrogen) for 24 h, then plated on poly-L-lysine-covered coverslips for 24 h. The coverslips were exposed to either 1% ascorbic acid or 10 µM isoproterenol for 10 min at 37°C, then fixed with 4% paraformaldehyde, pH 7.4, and mounted onto glass slides in Fluoromount G mounting media (Electron Microscopy Sciences, Hartfield, PA). Coverslips were sealed with clear nail polish and imaged within 24 h after fixation.

Sensitized Emission FRET Microscopy. FRET was recorded using the three-channel sensitized emission mode (Gordon et al., 1998Go). Donor channel for the CFP was acquired using donor excitation ({lambda} = 458 nm) and donor emission ({lambda} = 475-525 nm) BP filter. Acceptor channel (YFP) was acquired using acceptor excitation ({lambda} = 514 nm) and emission ({lambda} = 530 nm) LP filter. FRET was acquired using excitation ({lambda} = 458 nm) and emission ({lambda} = 530 nm) LP filter. Images were taken from donor, acceptor, and FRET samples. Donor and acceptor images were used to evaluate the cross-talk of signals that is caused by image settings and fluorophore properties. The same acquisition parameters were used for donor, acceptor, and FRET samples. The LSM 510 FRET Macro tool was used to calculate normalized FRET (FRETN) values. FRETN is a measure of FRET that is normalized for the concentrations of donor and acceptor fluorophores and therefore represents a fully corrected measure of FRET (Gordon et al., 1998Go). Quantitative comparisons of different FRET methods, has determined that FRETN provides the most accurate measure of FRET efficiencies (Gu et al., 2004Go). In this method, the corrected FRET value for each pixel is calculated and then divided by concentration values for donor and acceptor. FRETN was calculated on a pixel-by-pixel basis for the entire image and in regions of interest (marked by rectangles) using the equation of Gordon et al. (1998Go).

Formula(3)

The equation indicates the proportional ({infty}) relationship between FRETN and the concentrations of the interacting and noninteracting species. In the equation, [bound] represents the concentration of interacting pairs of donor labeled species and acceptor labeled species. The values for [total d] and [total a] represent the total concentrations (interacting and noninteracting) of the donor and acceptor labeled species, respectively. FRET1 is proportional to the FRET signal from the specimen; Dfd is the donor signal that would take place if no FRET occurred and is therefore proportional to the total concentration of donor; and Afa is the acceptor signal that would take place if no FRET occurred and is therefore proportional to the total concentration of acceptor.

Donor and acceptor coefficients were determined in the beginning of each experiment and were kept the same throughout. Donor, acceptor, and FRET thresholds were set to determine the background value. Threshold values were subtracted from all pixels before FRET calculations. Extreme values were excluded from both the FRET image as well as data table calculation. FRETN images are presented in pseudocolor mode.

Molecular Modeling of the Human beta1-AR. Homology modeling was performed with the program SegMod (Levitt, 1992Go). The program was used to optimally align the sequences of the human beta1-AR and bovine rhodopsin, and then the sequence of the beta1-AR was threaded onto the rhodopsin structure based upon the 1F88 (Palczewski et al., 2000Go) model of rhodopsin oligomers deposited in the Protein Data Bank. The resulting homology model was then refined according to SegMod protocols. The figures were produced using MOLSCRIPT and rendered with RASTER3D (Merrit and Bacon, 1997Go), which was also used to estimate the distances in Ångstroms between the various amino acids.


    Results
 Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 
The crystal structure of bovine rhodopsin showed that helices 3 and 6 of rhodopsin were extended {alpha}-helices that projected into the cytoplasm further than expected from hydropathy-based computer models (Palczewski et al., 2000Go). Thus, many residues that were previously assigned to intracellular loop 3 of rhodopsin actually constituted the cytoplasmic neck of helix 6. Among these are a pair of conserved lysine residues that would occupy locations one turn apart in putative helix 6 (Fig. 1). The arrangement of this pair of lysines to the same side of the 6th {alpha}-helix is conserved in the majority of class A GPCRs, such as {alpha}- and beta-adrenergic receptor families, dopamine receptors, and others. To examine whether these residues are involved in GPCR-mediated events, we mutagenized Lys321 and Lys324 in the human beta1-AR into three different amino acids. Each lysine was mutated to glutamic acid (Lys-> Glu) to fully reverse its charge, to methionine (Lys-> Met) to neutralize its charge and to mimic its protonated state with an amino acid of similar mass, and to alanine (Lys-> Ala) to fully remove the functionality of the side chain. These constructs were transiently transfected into HEK-293 cells, and the binding parameters for each mutant were compared with that of the WT beta1-AR (Table 1). The densities of the beta1-AR (KD) in each cell line were comparable and ranged from 0.9 to 1.2 pmol/mg of protein. The affinities of [125I]ICYP to the WT beta1-AR or to the mutants were comparable and ranged from 19 to 28 pM (p > 0.05), which is similar to the affinity of ICYP to this beta-AR subtype. These data indicate that mutagenesis of either lysine did not alter the binding characteristics of these receptors to antagonists.


Figure 1
View larger version (25K):
[in this window]
[in a new window]
 
Fig. 1. Alignment of a conserved pair of lysines within helix VI of different members of class A GPCR. The conserved lysines within helix 6 of the various GPCR are boxed. The abbreviations used are as follows: h{alpha}-AR, human {alpha}-adrenergic receptor; hbeta-AR, human beta-adrenergic receptors; hD-R, human dopamine receptor; hANGII-R, human angiotensinII; boRHO, bovine rhodopsin; hM-R, human muscarinic receptor; hADN-R, human adenosine receptor; h5HT-R, human serotonin receptor.

 

View this table:
[in this window]
[in a new window]
 
TABLE 1 Ligand binding parameters of the wild-type and mutants of the beta1-AR

Site directed mutagenesis of Lys321 and Lys324 to the amino acids indicated in the table was performed as described under Materials and Methods. [125I]ICYP binding was determined as described under Materials and Methods on membranes derived from HEK-293 cells expressing the wild-type beta1-AR or the different beta1-AR mutants. Saturation binding experiments were analyzed by nonlinear regression to determine the equilibrium dissociation constant (KD) of ICYP to each receptor and the receptor density in each membrane preparation. In HEK-293 cells, cell receptor densities for each beta1-AR construct were comparable and ranged from 850 to 1100 fmol of receptor/mg of protein. Competition binding isotherms were analyzed using the two-site competition algorithms in the Prism 4.0 program. When the binding data were best described by two affinity states, KIH and KIL indicate the dissociation constants for the high- and low-affinity state of the receptor, respectively. The results are the mean of four to six independent determinations each in triplicate.

 

Binding Characteristics of the WT beta1-AR versus the Lys321/324 Mutants. To determine the binding characteristics of each of these receptors to beta-agonists, competition of ICYP binding to membranes prepared from each cell line by isoproterenol in the absence of GTP were performed (Fig. 2A). As expected, the competition of ICYP binding to the WT beta1-AR by isoproterenol was shallow, and its parameters were estimated by fitting the data into a two-site binding model. Using these analyses, we estimated the two affinity states of the receptor (KIH = 2 ± 0.14 nM; KIL = 0.35 ± 0.02 µM) and the ratio of the high-versus the low-affinity receptor was 44 to 54%. Mutagenesis of Lys321 to the various amino acids described earlier had no significant effects on the high and low affinities of these receptors to isoproterenol or the proportion of low to high beta1-AR populations (Table 1). Mutagenesis of Lys324 to any of the three amino acids described before had significant effects on isoproterenol competition isotherms, whereby the data could be fitted into a one-site model with a single low binding affinity Ki of ~0.3 to 1.3 µM. Therefore, mutagenesis of Lys324 eliminated the high-affinity binding component to agonists without affecting the binding parameters of antagonists.


Figure 2
View larger version (15K):
[in this window]
[in a new window]
 
Fig. 2. Competition binding isotherms of isoproterenol on membranes expressing the WT beta1-AR (A) or the Lys324 beta1-AR mutants (B). [125I]ICYP binding was determined as described under Materials and Methods on membranes derived from HEK-293 cells expressing the wild-type beta1-AR or the Lys324 beta1-AR mutants. A, the competition isotherms were determined in either the absence (-GTP) or presence of 100 µM Gpp(NH)p (+GTP). B, the competition isotherm for the WT beta1-AR (-GTP) was plotted on the same plot as the competition isotherms for the indicated Lys324 beta1-AR mutants (-GTP). The results are representative of three to five experiments whose mean ± S.E. values are reported in Table 1.

 
When the stable GTP analog guanosine 5'-[beta-{gamma}-imido] triphosphate (GppNHp) was present in the competition experiment between isoproterenol and ICYP binding to membranes expressing the WT beta1-AR, the binding isotherm was shifted to the right and displayed a single low-affinity binding state to isoproterenol (Fig. 2A). The affinity of the WT beta1-AR in the presence of GppNHp was 0.35 ± 0.07 µM, the same as the KIL for isoproterenol and close to the affinity of the Lys324 beta1-AR mutants in binding to isoproterenol (Fig. 2A). Thus, in accordance with classic paradigm governing the law of mass action for receptor activation, guanyl nucleotides mediated the conversion of the WT beta1-AR from its high-affinity state into a low-affinity state (presumably uncoupled from the G protein). GppNHp, however, did not affect the binding parameters of isoproterenol to the Lys324 beta1-AR mutants, indicating that these receptors were insensitive to GTP-mediated uncoupling of the receptor from the G proteins.

Activation of Adenylyl Cyclase by the WT beta1-AR versus the Lys321/324 Mutants. First, we determined the effect of mutagenesis of Lys321 and Lys324 on the ability of the mutated beta1-AR to increase the concentration of cyclic AMP in cells in response to isoproterenol and on the coupling the beta-AR to adenylyl cyclase. Basal levels of cyclic AMP formation for the WT beta1-AR were equivalent to those of the Lys321 mutants but considerably higher than those of Lys324 mutants. For example, basal cyclic AMP for the WT beta1-AR was 14 ± 1.5 pmol/mg of protein, whereas in the K324A mutant, these levels were 4 ± 1 pmol/mg (p < 0.02). Basal cyclic AMP levels in the the K324A mutant were not significantly different from their levels in cells expressing empty pcDNA 3.1 (5 ± 2 pmol/mg).

The EC50 for the accumulation of cyclic AMP in response to increasing concentrations of isoproterenol was 7 ± 1.5 nM for the WT beta1-AR, and between 9 and 13 nM (p > 0.05) for the Lys321 or Lys324 mutants (Fig. 3, A and B). Cyclic AMP accumulation in response to 100 nM isoproterenol in cells expressing the WT beta1-AR was ~80 pmol/min/mg of protein, and these levels were consistently ~20% higher from those attained in cells expressing either the Lys321 or the Lys324 mutants (Fig. 3, A and B).


Figure 3
View larger version (17K):
[in this window]
[in a new window]
 
Fig. 3. Effect of mutagenesis of Lys321 or Lys324 in the beta1-AR on isoproterenol mediated increase in cyclic AMP accumulation or adenylyl cyclase activation. A and B, cells were transiently transfected with the empty mammalian expression vector (pCDNA), the WT beta1-AR or the various Lys321- or Lys324-beta1-AR mutant constructs. The receptor densities in the cells transfected with the various beta1-AR constructs ranged from 850 to 1100 fmol of receptor/mg of protein. Shown are the basal levels of cyclic AMP in the presence of 1 mM ascorbic acid (AA) or in the presence of 1, 10, 50, and 100 nM isoproterenol that were determined as described under Materials and Methods. For the Lys321 beta1-AR mutants, the results are the means of two independent experiments, whereas for the Lys324 beta1-AR mutants, the results are the means ± S.E. of four independent determinations, each in duplicate. C, isoproterenol-mediated activation of adenylyl cyclase in membranes prepared from cells expressing the WT beta1-AR or the K324A mutant were compared. The EC50 for the WT beta1-AR was 0.1 ± 0.02 µM, and the EC50 for the K324A mutant was 1.2 ± 0.3 µM(*p < 0.05, n = 5).

 
Basal levels of adenylyl cyclase activity in membranes prepared from cells expressing the WT beta1-AR were 18 ± 3 pmol/mg/min, whereas in cells expressing either the K324A mutant or the empty pcDNA vector, these levels were 7 ± 2 pmol/mg/min (p < 0.05). Basal adenylyl cyclase levels increased to 300 ± 47 pmol/mg/min upon exposing any of the three types of membranes to 10 µM forskolin. The EC50 for the activation of adenylyl cyclase activity in membranes expressing the WT beta1-AR was 0.1 ± 0.02 µM, whereas the EC50 for the K324A mutant was 10-fold higher at 1.2 ± 0.3 µM (Fig. 3C). Therefore, the lower basal levels of adenylyl cyclase activity in membranes expressing the K324A mutant were associated with a 10-fold reduction in the coupling affinity of the K324A mutant to adenylyl cyclase activation, but this mutant receptor was still capable of maximally activating the cyclase (Fig. 3C). These data indicate that ligand-independent coupling of the receptor to Gs was obliterated in the K324A mutant even though this construct retained its ability to activate Gs in response to agonists.


Figure 4
View larger version (15K):
[in this window]
[in a new window]
 
Fig. 4. Correlation between the affinity of various drugs for competing for ICYP binding for the K324A mutant versus the WT beta1-AR as a function of their intrinsic activities for each receptor. A, classic form of the ternary complex model. A, agent; R, receptor; G, G protein. These molecules interact with the equilibrium dissociation constants K, M, {alpha}M, and {alpha}K as described in De Lean et al. (1980Go). B, the KI of different drugs determined by competition for the binding of [125I]ICYP on membranes expressing either the wild-type beta1-AR or the K324A mutant was determined as described under Materials and Methods. The "affinity shift" is the ratio between apparent low and high affinities for the K324A mutant and the WT beta1-AR. The "intrinsic activity" for each adrenergic agent was derived as illustrated in the legend of Table 2. The results are the mean of three to five independent determinations, each in triplicate. C, micromolar KI values of different drugs that were determined by competition for the binding of [125I]ICYP on membranes expressing the K324A mutant were plotted against the "intrinsic activity" of each agent to the K324A mutant. The correlation coefficient for the linearity of the data in A and B was determined using Prism 4.05 software. Isoproterenol, 1; dobutamine, 2; norepinephrine, 3; epinephrine, 4; isoetharine, 5; terbutaline, 6.

 

View this table:
[in this window]
[in a new window]
 
TABLE 2 Ligand binding parameters of adrenergic agents to wild-type and K324A beta1-AR

Competition of [125I]ICYP binding by each drug was determined as described under Materials and Methods on membranes derived from HEK-293 cells expressing the wild-type beta1-AR or K324A. Cell receptor densities for the WT-beta1-AR were 1050 ± 180 fmol of receptor/mg of protein and for K324A they were 985 ± 110 fmol of receptor/mg of protein. Competition binding isotherms were analyzed using the two-site competition algorithms to estimate the means ± S.E. for the KIH and KIL for each drug. These data were derived from three to five determinations, each performed in triplicate. The `affinity shift' for the WT beta1-AR was calculated as the ratio between the apparent binding affinity for the low affinity binding site (KL) relative to the high affinity binding site (KH), which were derived from four independent competition determinations. The affinity shift for K324A was similarly calculated from four independent competition experiments. To calculate the `intrinsic activity' for each adrenergic agent, membranes were prepared from cells expressing either WT beta1-AR or K324A. Adenylyl cyclase activation in 50 µg of each type of membrane by increasing concentrations of each beta-agonist was determined as described under Materials and Methods. The intrinsic activity indicates the ratio between maximal adenylyl cyclase activation in picomoles per minute per milligram of protein elicited by each drug to that obtained with the full agonist isoproterenol. The results are the mean of three to five independent determinations each in triplicate. These data were used for plotting the data in Fig. 4, B and C.

 
Validation of the Assumptions of Ternary Complex Model in Accounting for the Properties of the Lys324 beta1-AR Mutant. The TCM is the most widely used model to describe the activation of GPCR. As shown in Fig. 4A, the TCM is concerned with three species, the agonist, [A], the receptor, [R], and the G protein, [G], and assumes that the active form of the GPCR consists of a ternary complex of [ARG] (De Lean et al., 1980Go). These species react via four equilibrium reactions that are governed by the law of mass action and are described by three affinity constants. The three affinity constants are M, {alpha}, and K. M describes the ligand-independent interaction of the receptor with the G protein. {alpha}, also called the coupling constant, is the ratio between the affinities of [A] for the two forms of the receptor [R] and [RG], which reflects the ability of [A] to promote the formation of the [ARG] complex (Kent et al., 1980Go). K is the affinity constant that describes the affinity of [A] in binding to [R] in the absence of [G]. The value of K is not related to the {alpha} coupling constant, indicating that the drug affinity and intrinsic activity (i.e., the maximal physiological response for a given agonist) are not correlated (Samama et al., 1993Go).

A fundamental assumption of the TCM, therefore, is that the log value of {alpha} and the intrinsic activity are correlated (Kent et al., 1980Go). The value for {alpha} is determined in competition isotherms between a constant concentration of the labeled antagonist and increasing concentrations of agonist, followed by estimating the two binding affinities using twosite modeling algorithms (Kent et al., 1980Go). To determine whether the WT beta1-AR and/or the K324A mutant adhered to the assumptions of the TCM, we examined the ligand binding properties of a series of full and partial agonists. First, we determined the intrinsic activity of each drug in membranes expressing either the WT beta1-AR or the K324A mutant as the ratio of its maximal activation of adenylyl cyclase to that attained by the prototypic full agonist isoproterenol (Table 2). The affinities of each drug for the WT beta1-AR or the K324A mutant were then determined by competition experiments between each drug and a fixed concentration of [125I]ICYP (Table 2). The intrinsic activity of each compound for the WT beta1-AR was plotted as a function of its log-affinity shift for the WT beta1-AR (Fig. 4A). A very significant correlation (r2 = 0.98) was found between the intrinsic activity of each compound for the WT beta1-AR and the extent of its log-affinity shift (Fig. 4A). Therefore, the WT beta1-AR obeyed the assumptions of the TCM model for these drugs. When we examined the data for the K324A mutant, we found that none of the drugs tested displayed a significant log-affinity shift toward the K324A mutant (Table 2 and Fig. 4A). Therefore, a plot of the intrinsic activity versus log shift in affinity for the K324A mutant was non linear, indicating that mutagenesis of Lys324 in the human beta1-AR interfered with the ability of receptor-mediated activation of adenylyl cyclase to obey the assumptions of the TCM. The K324A mutation promoted the formation of a single low-affinity binding site that was insensitive to GTP. Under these conditions, the TCM predicts that the affinity of [A] to [R] that is described by the value of the equilibrium binding constant (K) in Fig. 4A, for the various beta-adrenergic agents in binding to the K324A mutant might be correlated with their intrinsic activity. Therefore, we plotted the KI values for the six beta-adrenergic agonists in competing for ICYP binding to membranes expressing the K324A mutant versus their intrinsic activities toward the K324A mutant (Fig. 4C). These values were correlated, indicating that the K324A mutant behaved as predicted by the TCM under conditions of G ~ 0 or low probability of [R] + [G] to spontaneously form [RG], which is reflected by the value of M (Fig. 4A).

There are other interesting observations concerning the high-affinity binding site for agonists in GPCR, in that the proportion of these sites can be increased by high molar excesses of synthetic peptides corresponding to the carboxylterminal region of the Gs{alpha} subunit (Palm et al., 1990Go; Rasenick et al., 1994Go). The generation of the high-affinity binding site in cells or membranes is thought to involve the binding of the Gs{alpha} carboxyl-terminal peptide to a region in the beta-AR that is involved in generating the high-affinity state of the receptor to agonists (Rasenick et al., 1994Go). Through this mechanism, these peptides presumably engage the receptor molecules and convert them into a high-affinity state for agonists.

Our first goal was to replicate these findings in membranes prepared from cells expressing the WT beta1-AR. For this purpose, the membranes were preincubated with a 200 µM concentration of the 11-mer Gs{alpha} carboxyl-terminal peptide or a control scrambled peptide, then the binding of [125I]ICYP to these membranes was competed with increasing concentrations of isoproterenol. The data in Fig. 5 show that in the presence of the control peptide, 48 ± 7% of the WT beta1-AR displayed a high-affinity state of 1.6 nM for isoproterenol. In the presence of the Gs{alpha} carboxyl-terminal peptide, the proportion of WT beta1-AR that displayed the high-affinity state almost doubled to ~90 ± 7%, but their affinity (1.6 nM) was similar to that of the KIH of the WT beta1-AR in the presence of control peptide or in membranes expressing the WT beta1-AR (Table 1). Therefore, the Gs{alpha} peptide acted as a Gs mimic to increase the proportion of high-affinity binding sites without altering the affinity (KIH) of the WT beta1-AR. Next, we tested the effect of these peptides on membranes expressing the K324A mutant (Fig. 5). In the presence of the control peptide, these membranes displayed a single low-affinity binding site of KI = 1 µM. However, in the presence of the Gs{alpha} carboxylterminal peptide, it was evident that the isoproterenol competition curves were shallow. Analysis of the competition isotherms indicated that these curves were best fitted into a two-site model with a KIH of 3 nM (42%) (p > 0.05 between the KIH of the WT beta1-AR and KIH of the K324A mutant plus Gs{alpha} peptide) and a KIL of 1 µM (58%) for isoproterenol. We tested the effect of these peptides on basal and isoproterenol-stimulated adenylyl cyclase activities in membranes expressing WT beta1-AR or the K324A mutant, but these experiments were not feasible because Gs{alpha} carboxyl-terminal peptides inhibit isoproterenol-mediated activation of adenylyl cyclase in permeabilized cells and membranes because they compromise the normal coupling of the agonist-activated receptor to Gs (Rasenick et al., 1994Go).


Figure 5
View larger version (26K):
[in this window]
[in a new window]
 
Fig. 5. Effect of the Gs{alpha} carboxyl-terminal peptide on the competition binding isotherms of isoproterenol on membranes expressing WT beta1-AR or the K324A mutant. [125I]ICYP binding was determined as described under Materials and Methods on membranes derived from HEK-293 cells expressing the wild-type beta1-AR or the K324A mutant. The competition isotherms were determined in either the presence of 200 µM of an 11-amino-acid control peptide (Arg-Gln-Leu-His-Leu-Met-Glu-Tyr-LeuGln-Arg) or in the presence of a 200 µM concentration of the 11-amino carboxyl-terminal Gs{alpha} peptide (Gln-Arg-Met-His-Leu-Arg-Gln-Tyr-Glu-Leu-Leu). Analysis of the isoproterenol-competition binding isotherms resulted in a KIH of 1.6 nM (RH = 48%) and KIL of 1.4 µM(RL = 52%) for the WT beta1-AR in the presence of control peptide. In the presence of the carboxyl-terminal Gs{alpha} peptide, the data for isoproterenol competition of ICYP binding to the WT beta1-AR could be fitted into a single site with a KI of 1.6 nM. Competition of ICYP binding to membranes expressing the K324A mutant in the presence of the control peptide could be fitted into a single low-affinity binding site with a KI of 1 µM. In the presence of the carboxyl-terminal Gs{alpha} peptide, the data for isoproterenol competition of ICYP binding to the K324A mutant could be confidently fitted into a two-site model with a KIH of 3 nM(RH = 42%) and KIL of 1 µM(RL = 58%). The results are representative of three experiments each in quadruplicates.

 

Characterization of the Distribution and Recycling of the WT beta1-AR and the K324A Mutant by Confocal Microscopy. To investigate whether the K324A mutation affects the localization of the beta1-AR in HEK-293 cells, cells stably expressing the Flag-tagged WT beta1-AR or the K324A mutant were labeled for 1 h at 37°C with FITC-conjugated anti-Flag IgG, then fixed and imaged with the Zeiss LSM-510 (Fig. 6A). The confocal images showed that the WT beta1-AR and the K324A mutant were expressed in the cell membrane (Fig. 6A, a and h). Exposing these cells to isoproterenol for 30 min promoted the internalization of WT beta1-AR into distinct intracellular punctate vesicular structures that are associated with the internalized GPCR phenotype (Fig. 6A, b and i). The cells were then exposed to mild acidic conditions to strip off the FITC-labeled IgG from the surface of the cell to visualize the internalized receptor populations (Fig. 6A, c and j). The images show that isoproterenol promoted equivalent internalization of WT beta1-AR and the K324A mutant. To determine the recycling kinetics of the various beta1-AR constructs, the cells were exposed to the beta-antagonist alprenolol to inhibit receptor internalization so that recycling could be accurately measured by the confocal recycling assay. The WT beta1-AR and the K324A mutant recycled rapidly (Fig. 6A, d-g and k-n) with equivalent recycling kinetics of t1/2 of 17 ± 5 min (Fig. 6B). Therefore, mutagenesis of Lys324 did not affect the distribution, internalization, or recycling of the K324A mutant.


Figure 6
View larger version (27K):
[in this window]
[in a new window]
 
Fig. 6. Characterization of the distribution, internalization, recycling, and phosphorylation of the wild-type beta1-AR versus the K324A mutant. A, HEK-293 cells stably expressing Flag-tagged WT beta1-AR or Flag-tagged K324A mutant were labeled with FITC anti-Flag IgG for 1 h, followed by 10 µM isoproterenol for 30 min. The cells were acid-washed and treated with 100 µM alprenolol for the times indicated in the figure. At the end of each alprenolol time point, the slides were fixed and visualized by confocal microscopy (n = 3). Each scale bar represents 5 µm. B, the LSM-510 software was used to determine the density of the pixels inside the circular boundary whose circumference was delimited 300 nm inside the cell. The pixels inside the boundary in isoproterenol/acid washed cells was set arbitrarily to 100% to indicate 100% internalization and the ratios in alprenolol-treated cells were calculated as a percentage at each time period. The t1/2 for recycling was calculated by fitting the relevant data to a single exponential function of time that were described in eq. 2. C, cells expressing the Flag-tagged WT beta1-AR or the Flag-tagged K324A mutant were metabolically labeled with 32PO4, then exposed to buffer (ascorbic acid 1%, denoted as -in the figure) or 10 µM isoproterenol for 10 min. The beta1-AR was immunoprecipitated using anti-Flag IgG-agarose and subjected to SDS-PAGE and autoradiography. 32P incorporated into each band were counted electronically using the PerkinElmer InstantImager.

 
Characterization of Isoproterenol-Mediated Phosphorylation of WT beta1-AR and the K324A Mutant. Agonist-mediated activation of GPCR is associated with phosphorylation of these receptors, which is a prelude to their desensitization and internalization. We compared basal and isoproterenol-mediated phosphorylation of these receptors in cells expressing equivalent amounts of receptor densities (Fig. 6C). As shown in Fig. 6C, exposure of cells expressing either the WT beta1-AR or the K324A mutant to isoproterenol resulted in receptor phosphorylations that were rapid (maximal response occurred in ~ 3 min) and resulted in a 490 ± 70% increase in 32P-incorporation above basal levels (n = 4). Therefore, the K324A mutation did not alter either basal or agonist-stimulated phosphorylation of this receptor.

Effect of the K324A Mutation on the Interaction of the beta1-AR with the Gs{alpha} Subunit. The K324A mutant displayed a single low-affinity binding site for agonists that we hypothesize resulted from its low affinity toward GDP-Gs. To examine the molecular basis of this intriguing phenomenon, we determined whether the WT beta1-AR interacted differently from the K324A mutant with the Gs{alpha} subunit. These interactions were assessed by FRET microscopy, which relies on the transfer of energy from an excited donor CFP to an acceptor YFP that occurs when the two tagged proteins are in very close proximity (<50 Å; Gordon et al., 1998Go). YFP was fused in-frame downstream from the carboxyl terminus of the beta1-AR. Gs{alpha}-CFP contains CFP inserted into the {alpha}1/{alpha}A loop of Gs{alpha}, the site of alternative splicing of Gs{alpha}; like WT Gs{alpha}, it was expressed in the membrane and displayed activity comparable with that of Gs{alpha} (Hynes et al., 2004Go). Before the initiation of FRET, the localization, internalization, and recycling of beta1-AR-YFP in HEK-293 cells was determined by confocal microscopy (Fig. 7A).


Figure 7
View larger version (45K):
[in this window]
[in a new window]
 
Fig. 7. Sensitized emission FRET microscopy between the WT beta1-AR and the Gs{alpha} subunit or the K324A mutant and the Gs{alpha} subunit. A, cells expressing WT beta1-AR-YFP were exposed to 10 µM isoproterenol for 30 min to internalize the beta1-AR, then the recycling of the receptor was visualized by confocal microscopy as described in the legend of Fig. 6. B and C, cells coexpressing the WT beta1-AR-YFP and Gs{alpha}-CFP (B) or the K324A mutant-YFP and Gs{alpha}-CFP (C) were exposed to ascorbic acid (-ISO) or 10 µM isoproterenol for 10 min at 37°C. The slides were fixed with 4% paraformaldehyde and imaged as described under Materials and Methods. FRETN is presented in pseudo color. Normalized FRETN values were calculated using the LSM510 Macro 1.5 FRET software (with eq. 3) that was described under Materials and Methods.

 
To determine the basal magnitude of FRET between the beta1-AR and Gs{alpha} in HEK-293 cells, WT beta1-AR-YFP or the K324A mutant-YFP were transiently transfected with Gs{alpha}-CFP into HEK-293. The cells were fixed and the normalized FRETN technique as measured by the sensitized emission method (Gordon et al., 1998Go) was used to determine the binding of each receptor to Gs{alpha} (Fig. 7B). In the absence of isoproterenol, the WT beta1-AR associated with Gs{alpha} with a FRETN efficiency of 2.3 ± 1.1%, whereas the FRETN efficiency between the K324A mutant and Gs{alpha} was not detectable (FRETN = 0, n = 3). These data indicate that in unstimulated cells, a small proportion of the WT beta1-AR population were in close proximity to Gs{alpha}, but within the sensitivity of this FRET assay, close proximity between the K324A mutant and Gs{alpha} could not be demonstrated. In cells that were fixed after the addition of 10 µM isoproterenol for 10 min, FRETN between the WT beta1-AR and Gs{alpha} was 27 ± 2%, whereas the comparable FRETN between the K324A mutant and Gs{alpha} was 5 ± 1.3% (n = 3, p < 0.01). Therefore, in response to isoproterenol-induced conformational changes in the beta1-AR, a large percentage of WT beta1-AR population was in close proximity to Gs{alpha}, whereas under the same conditions, a comparably much smaller population of the K324A mutant interacted or was in close proximity to Gs{alpha}.

Three-Dimensional Modeling of the 6th {alpha}-Helix of the Human beta1-AR. In Fig. 8, the distribution of Lys321 and Lys324 in helix 6 relative to the (D/E)RY motif in helix 3 are displayed based upon the crystal structure of dark-adapted bovine rhodopsin (Palczewski et al., 2000Go). In Table 3, we provide the distance in Å between the {alpha}-carbons of the amino acids in the cytoplasmic terminus of helix 6 and the {alpha}-carbon in each amino acid of the (D/E)RY sequence in helix 3 of the human beta1-AR. The closest residue to the (D/E)RY motif was Lys324, followed by Leu323 and Gln320. Sheikh et al. (1999Go) probed the microdomains in the beta2-AR that are involved in coupling this receptor to Gs by a zinc(II) bridging method. In this method, each residue in helix 6 was mutated to a histidine. Likewise, Ala134 in helix 3 [that lies one turn away from the (D/E)RY motif] was also mutated to a histidine. Therefore, if the distance between the pair of histidines in helices 3 and 6 was <11Å, zinc(II) bridges would form between them. The formation of these zinc(II) bridges would prevent the separation of helix 3 from helix 6 in response to agonistmediated activation of the beta2-AR and therefore, would prevent the activation of Gs that is measured by guanosine 5'-O-(3-thio)tri-[32P]phosphate binding to membranes. Under these conditions, it was shown that histidine substitutions of Glu268, His269, and Leu272 in helix 6 of the human beta2-AR prevented agonist-mediated activation of Gs as indexed by 5'-O-(3-thio)triphosphate binding. The corresponding residues in the human beta1 -AR are Glu319, Gln320, and Leu323, which according to the data in Table 3 are separated by <12Å from the (D/E)RY amino acids in helix 3. Sheikh et al. (1999Go) however, could not identify the residue in helix 6 that was involved in imparting the high-affinity binding of the beta2-AR to agonists. Using pharmacological, biochemical and ultrastructural approaches, we determined that Lys324 in helix 6 was involved in this phenomenon and that it was the closest amino acid in helix 6 to the (D/E)RY motif in helix 3.


Figure 8
View larger version (61K):
[in this window]
[in a new window]
 
Fig. 8. Structural model of the transmembrane helices of the human beta1-AR based upon the crystal structure of dark-adapted bovine rhodopsin. The amino acids in the transmembrane helices of the human beta1-AR and rhodopsin were aligned according to the three-dimensional data of Palczewski et al. (2000Go) by the SegMod computer program (Levitt, 1992Go). Using the aligned sequence of the beta1-AR, we threaded the sequence into that of the rhodopsin structure and refined the structure to build a structurally valid model. The figure was produced using MOLSCRIPT and rendered with RASTER3D computer programs. The figure shows the distribution of the various transmembrane helices of the human beta1-AR. Structural details of the various amino acids in the cytoplasmic termini of helices 3 and 6 were calculated from the coordinates.

 

View this table:
[in this window]
[in a new window]
 
TABLE 3 Estimation of the distance between the (E/D)RY motif in helix 3 and the various residues in helix 6 of the human beta1-AR by the three-dimensional model of rhodopsin as described by Palczewski et al. (2000Go)

The distances were estimated from the SEGMOD-generated three-dimensional image of rhodopsin in Fig. 8.

 


    Discussion
 Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 
From the effects of mutagenesis of lysine at position 324, we infer that this residue in the human beta1-AR is involved in imparting the high-affinity binding state of the receptor to agonists. This high affinity state is thought to result from the association of the receptor with the appropriate G protein because addition of GTP reduces the agonist binding affinity by promoting the dissociation of the {alpha} and beta{gamma} subunits of Gs from the receptor and from each other. These observations were confirmed in mouse lymphoma S49 CYC- cells that genetically lack the {alpha}-subunit of Gs and display a single low-affinity binding constant for agonists to the beta2-AR (Haga et al., 1977Go; Ross et al., 1977Go). Conversely, the affinity of antagonists to GPCR was not affected by GTP or by the genetic absence of the G protein in CYC- S49 cells. Likewise, the affinity of the K324A mutant for antagonists was similar to the affinity of the WT beta1-AR to these agents. The ability of G proteins to modulate the binding of agonists, but not antagonists, suggests a reciprocal interaction between the receptor-G protein interface and the agonist-binding pocket (Sheikh et al., 1999Go).

How this reciprocity is mediated is currently unknown. In rhodopsin, light induces a conformational change that enhances the affinity of rhodopsin for the binding of the retinal G protein transducin (Zuyga et al., 1994Go). Transducin in turn stabilizes a spectral form of rhodopsin called metarhodopsin II that is generated after light-mediated "activation" of rhodopsin. The activation of transducin is thought to occur by light-induced movement of helix 6 relative to helix 3 in rhodopsin (Farrens et al., 1996Go). In analogy to rhodopsin, separation of helix 3 from helix 6 in many GPCRs was identified as the major conformational hallmark of agonist-mediated activation of these receptors (Javitch et al., 1995Go; Elling et al., 1997Go; Gether et al., 1997Go; Ballesteros et al., 2001).

Compared with the WT beta1-AR, membranes expressing the the K324A mutant displayed lower affinity in binding to isoproterenol and displayed significantly lower basal levels of cyclic AMP. Moreover, the EC50 for isoproterenol in activating adenylyl cyclase in membranes expressing the K324A mutant was 10-fold higher than its comparable EC50 in membranes expressing the WT beta1-AR. These data suggest that separate amino acids might be involved in high-affinity binding to agonists versus agonist-mediated activation of the G protein. Through the engineering of Zn2+ binding domains in the human beta2-AR, Sheikh et al. (1999Go) discovered that amino acids in helix 6 that were in close proximity to the G proteinbinding residues in helix 3 were involved in the activation of Gs. Thus, Glu268, His269, and Leu271 in helix 6, which were the closest to the (D/E)RY residues in helix 3, were involved in agonist-mediated activation of the G protein, but had no effect on agonist binding affinity. Under these experimental conditions, Lys272 in the beta2-AR (which corresponds to Lys324 in the beta1-AR) was not involved in either G protein activation or high-affinity binding because its distance from Leu134 in helix 3 was estimated to be >12.5 Å (Sheikh et al., 1999Go). In this report, we show by biochemical, pharmacological, cell biological, and structural criteria that Lys324 in involved in imparting high-affinity binding characteristics to agonist. The discrepancy between our data and that of Sheikh et al. (1999Go) is due mostly to differences in the three-dimensional models that were used and the residues for which distances were calculated. First, Sheikh et al. (1999Go) relied on the Baldwin three-dimensional model for rhodopsin derived from electron diffraction (Baldwin et al., 1997Go), which preceded the Palczewski et al. (2000Go) model derived from X-ray diffraction of rhodopsin crystals to estimate the distances among the various amino acids. Second, we measured the distances between amino acids in helix 6 and the individual (D/E)RY amino acids in helix 3, whereas Sheikh et al. (1999Go) estimated the distances between the various amino acids in helix 6 and Leu134, which lies one turn away from the (D/E)RY sequence. Our data in Table 3 are derived from a different set of parameters than those used by Sheikh et al. (1999Go), and we believe our parameters provide a more objective analysis and reveal that Lys324 is the closest residue to the (D/E)RY motif among those in helix 6. Nevertheless, both models are consistent with the notion that separate entities in the GPCR are responsible for high-affinity binding and G protein activation through amino acids in helix 6 that lie in close proximity to the (D/E)RY motif in helix 3 (Table 3). Furthermore, a role for Leu323 in regulating the coupling of the beta1-AR to the G protein and a role Glu318 and Gln319 in the serotonin2A receptor (that corresponds to Glu319 and Gln320 in the beta1-AR) have been established (Lattion et al., 1999Go; Shapiro et al., 2002Go).

The TCM was introduced to mathematically model the observation that agonists, but not antagonists, stabilize an activated conformation of the receptor (De Lean et al., 1980Go). In the TCM, the affinity constant (M) describes the ligand-independent interaction between the receptor and the G protein (Fig. 4A). Our results in Figs. 3 and 4 indicate that basal activity of adenylyl cyclase in the K324A mutant membranes was significantly lower that that in WT beta1-AR membranes. Likewise, basal cyclic AMP accumulation in cells expressing the K324A mutant was significantly less than in cells expressing the beta1-AR. These two pieces of data suggest that the value of M between the K324A mutant and Gs is apparently much less than the value for M between the WT beta1-AR and Gs.

Concerning {alpha}, we observed a strong correlation between the drug's intrinsic activity and log {alpha} values for competition of these drugs to the WT beta1-AR (Fig. 4B). For the K324A mutant, however, there was no correlation because {alpha} = 1 (i.e., log {alpha} = 0). The TCM and the law of mass action both predict that {alpha} ~ 1 in conditions where the levels of the appropriate G protein are very low, such as in S49 CYC- cells or when experimentally generated in the presence of Gp-p(NH)p (Haga et al., 1977Go; Ross et al., 1977Go). Under these conditions, theoretical binding isotherms modeled after the TCM or the law of mass action display a single class of binding sites. Accordingly, our data for the K324A mutant are consistent with the assumption that G is apparently ~ 0. Concerning the third constant (K), which describes the affinity of [A] in binding to [R] in the absence of [G] (Fig. 4A), we found that the affinity of drugs to the WT beta1-AR and their intrinsic activities were not correlated, which is expected. However, for the K324A mutant, there was an excellent correlation between the affinity of a drug in binding to the K324A mutant and its intrinsic activity. Again, our data seem to support the notion that the K324A mutant was behaving as if G ~ 0. In the absence of the G protein, the TCM becomes analogous to the so-called allosteric receptor model for a monomeric receptor that was fashionable for interpreting ligand-receptor interactions before the TCM (Thron, 1973Go; Furchgott, 1978Go). This model predicts binding curves with unitary slope factors consistent with homogeneous class of binding sites, in which K is the affinity constant that describes the equilibrium constant forFormula

which describes agonist-mediated binding and subsequent activation of the receptor in the absence of [G] (Colquhoun, 1973Go). In this case, a correlation between the unitary affinity of the receptor and its intrinsic efficacy is observed, which is the case for the K324A mutant.

The situation in cells expressing the K324A mutant is not analogous to a G protein-free system, because immunoreactive levels of the Gs{alpha} subunit in cells expressing the WT beta1-AR and the K324A mutant wer